Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study
| Autor: | Anant Mohan, Jain Amit, Mirza Masroor, A Imtiyaz, Rashid Mir, P. C. Ray, Y. Prasant, Jamsheed Javid, Alpana Saxena, Z Mariyam |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Risk Cancer Research medicine.medical_specialty Pathology Lung Neoplasms Genotype Epidemiology Homozygous genotype India Adenocarcinoma of Lung Adenocarcinoma Polymorphism Single Nucleotide Gastroenterology Epidermal growth factor Carcinoma Non-Small-Cell Lung Internal medicine Biomarkers Tumor Humans Medicine Genetic Predisposition to Disease Allele Aged Aged 80 and over Lung Epidermal Growth Factor business.industry Public Health Environmental and Occupational Health Case-control study Middle Aged Prognosis medicine.disease medicine.anatomical_structure Oncology Case-Control Studies Female Non small cell business |
| Zdroj: | Asian Pacific Journal of Cancer Prevention. 16:7529-7534 |
| ISSN: | 1513-7368 |
| Popis: | BACKGROUND The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism in the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population. MATERIALS AND METHODS This case- control study included 100 histopathologically confirmed NSCLC (ADC) patients and 100 healthy controls. EGF (A61G) was genotyped by AS-PCR to elucidate putative associations with clinical outcomes. The association of the polymorphism with the survival of NSCLC patients was estimated by Kaplan-Meier curves. RESULTS It was found that EGF 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of NSCLC (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p=0.005) and homozygous GG (p=0.009)]. Patients homozygous for the G allele exhibited a significantly poor overall survival. The median survival time for patients with EGF 61 AA, AG, and GG genotypes was 10.5, 7.4, and 7.1 months (p=0.02), respectively. NSCLC (ADC) patients with GG + AG exhibited 7.3 months median survival compared to the AA genotype (p=0.009). CONCLUSIONS The present study revealed that the EGF A61G genotype may be a novel independent prognostic marker to identify patients at higher risk of occurrence and an unfavourable clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|